Please login to the form below

Not currently logged in
Email:
Password:

axi-cel

This page shows the latest axi-cel news and features for those working in and with pharma, biotech and healthcare.

New trial results suggest CAR-T effects are durable in lymphoma

New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts. ... Celgene and Juno are hoping to crash the party soon with their

Latest news

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    At a stroke, Gilead becomes a front-runner in the race to bring the first CAR-T to market with Novartis, claiming Kite's late-stage candidate axicabtagene ciloleucel (axi-cel ... Kite also has a pipeline of other CAR-T therapies following behind axi-cel,

  • Kite starts EU trial of lead CAR-T therapy Kite starts EU trial of lead CAR-T therapy

    Kite Pharma has treated its first European patient with axicabtagene ciloleucel (KTE-C19 or axi-cel), its CAR-T therapy for B-cell lymphomas. ... The start of the trial comes after Kite has already filed for approval of axi-cel in the EU based on the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Headline. $m. Kite (US). Gilead (US). Company acquisition. CAR-T technology with lead product ‘axi-cel’ under priority review at the FDA for treatment of refractory aggressive NHL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics